Chugai Pharmaceutical (OTCMKTS:CHGCY – Get Free Report) released its quarterly earnings data on Friday. The company reported $0.22 EPS for the quarter, Zacks reports. The business had revenue of $2.14 billion for the quarter, compared to the consensus estimate of $2.38 billion. Chugai Pharmaceutical had a net margin of 34.98% and a return on equity of 22.90%.
Chugai Pharmaceutical Stock Performance
OTCMKTS:CHGCY opened at $21.87 on Friday. Chugai Pharmaceutical has a 52-week low of $19.50 and a 52-week high of $34.84. The firm has a market cap of $71.98 billion, a price-to-earnings ratio of 23.77 and a beta of 0.59. The business’s fifty day moving average is $23.40 and its 200 day moving average is $26.40.
Analyst Upgrades and Downgrades
Several equities analysts have recently weighed in on the stock. Zacks Research upgraded shares of Chugai Pharmaceutical to a “hold” rating in a research note on Friday, May 29th. The Goldman Sachs Group upgraded shares of Chugai Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Monday, June 15th. Two research analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy”.
About Chugai Pharmaceutical
Chugai Pharmaceutical Co, Ltd. is a Japan-based biopharmaceutical company headquartered in Tokyo that focuses on the discovery, development, manufacture and marketing of prescription medicines. The company develops both biologics and small-molecule therapies, with particular emphasis on oncology and immunology as well as treatments for bone and metabolic disorders. Chugai’s activities span the full drug lifecycle from early research and clinical development through regulatory approval, manufacturing and post-marketing support.
Chugai is known for its research-driven approach and its work on monoclonal antibodies and other biologic therapeutics.
Recommended Stories
- Five stocks we like better than Chugai Pharmaceutical
- Telecom Earnings Reveal a Sector That Finally Looks Healthier
- Defense Earnings Show Readiness Now and Modernization Ahead
- Why Palantir Investors Aren’t Panicking While the Rest of AI Sells Off
- MarketBeat Week in Review – 07/20- 07/24
Receive News & Ratings for Chugai Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chugai Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
